Peter Clark, MA, MD, FRCP: A Payer Perspective

First International Summit on Interventional Pharmacoeconomics

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Apr

Today In Oncology

Peter Clark, MA, MD, FRCP: A Payer Perspective

Related Videos

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Small Phase II Study Examines Triplet Regimen for Patients With HER2-Positive Breast Cancer and Leptomeningeal Metastasis

Long-Term Outcomes With Pralsetinib in RET Fusion–Positive NSCLC

IMPT vs IMRT in Oropharyngeal Cancer

Metastatic Papillary Renal Cancer Final Results With Savolitinib and Durvalumab

Damaging Missense Variants in Innate Immunity Genes Linked to Earlier Breast Cancer Onset in BRCA1 Carriers